Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Good Life Plus

    MCap

    GBP12m

    Last close

    GBP0.02

    ▲ 0.40 (22.86%)

    KEFI Gold and Copper

    MCap

    GBP39m

    Last close

    GBP0.01

    ▲ 0.11 (20.00%)

    OSE Immunotherapeutics

    MCap

    EUR132m

    Last close

    EUR6.14

    ▲ 0.68 (12.45%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oxford Cannabinoid Technologies (LSE: OCTP)

Last close As at 02/07/2024

0.17

▲ −0.04 (−19.05%)

Market capitalisation

2m

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Update

Oxford Cannabinoid Technologies — Early signs of revival in clinical activity

Healthcare | edison tv

Oxford Cannabinoid Technologies – executive interview

Healthcare | Flash note

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Healthcare | Update

Oxford Cannabinoid Technologies — Clinical headway rests on funding
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (52.8) (61.4) (83.4)
Relative (53.5) (64.2) (84.9)
52 week high/low 1.3p/0.1p

Financials

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Apr Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.0 (5.1) (5.1) (0.49) N/A N/A
2023A 0.0 (6.9) (7.0) (0.61) N/A N/A
2024E 0.0 (3.4) (3.4) (0.22) N/A N/A
2025E 0.0 (4.0) (4.0) (0.29) N/A N/A

Research

edison tv

Healthcare

Oxford Cannabinoid Technologies – executive interview

Flash note

Healthcare

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Healthcare

Update

Oxford Cannabinoid Technologies — Early signs of revival in clinical activity

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free